Peripheral neuropathy decisions — 2025

The appeal was dismissed due to the Veteran's death.

The Board granted a 20 percent rating for right lower extremity peripheral neuropathy and an earlier effective date of June 1, 2021, for the grant of service connection for RLE PN.

The Board denied the Veteran's claim for a rating higher than 10 percent for upper back dermatome at T1-T3 (also claimed as peripheral neuropathy, upper back) based on moderate incomplete paralysis.

The Board denied service connection for ischemic heart disease, hypertension, erectile dysfunction, headaches, and other conditions as the evidence did not support a finding that these disabilities were incurred in or caused by service, to include due to exposure to an herbicide agent.

The Board granted separate awards of special monthly compensation (SMC) at the (l), (o), and (r)(1) rates based on the Veteran's service-connected Parkinson's disease with physical impairments, in addition to his existing SMC for a psychiatric disorder.

The Board granted service connection for diabetes mellitus type II, coronary artery disease, hypertension (under the PACT Act), erectile dysfunction as secondary to diabetes, and diabetic nephropathy. The claims for depression, right upper extremity peripheral neuropathy, left upper extremity peripheral neuropathy, right lower extremity peripheral neuropathy, and left lower extremity peripheral neuropathy were denied.

The Board granted service connection for left and right hip arthritis but denied it for right upper peripheral neuropathy, left shoulder disability, and right shoulder disability. The claims for left and right hand disabilities were remanded.

The Board denied earlier effective dates for the veteran's service-connected conditions, except for diabetes mellitus type II which was granted an effective date of February 25, 2019.

The appeal regarding entitlement to service connection for a kidney condition is dismissed, and the claims for service connection for arthritis and peripheral neuropathy in both upper and lower extremities are remanded.

The Board granted service connection for diabetes mellitus type II, right and left lower extremity diabetic peripheral neuropathy, and coronary artery disease based on herbicide exposure in Thailand.

The Board granted service connection for neuropathy in both lower extremities, due to herbicide exposure, on a direct basis. The claims for gout in both lower extremities were remanded for further development.

The Board denied the veteran's claim for service connection for bilateral lower extremity peripheral neuropathy, finding no evidence of a current disability.

The Board denied service connection for asthma, COPD, hemorrhoids, a heart condition, left wrist and thumb conditions, right forearm/elbow condition, lower extremity peripheral neuropathies, and upper extremity peripheral neuropathies as there was no evidence of an in-service event, injury, or disease relevant to these conditions and a nexus between any such occurrence and the present diseases.

The Board denied service connection for right and left upper extremity peripheral neuropathy, hypertension, CAD, and the Veteran's cause of death. The claims for a survivor's pension were also remanded.

The Board denied the claims for increased ratings for left hand peripheral neuropathy and left wrist fracture status post bone graft, finding that the evidence did not support a higher rating.

The Board remands the issues of service connection for peripheral neuropathy and a bilateral shoulder disorder due to challenges regarding the competency of the medical examiner.

The Board granted a separate evaluation of 20 percent for neuralgia in both the left and right lower extremities, but denied an increased rating for peripheral neuropathy in both lower extremities.

The Board remands the claims for service connection for various conditions to allow the AOJ to provide notice of the Veteran's right to a hearing and determine if additional evidentiary development is required.

The Board denied higher ratings for diabetes mellitus and peripheral neuropathy, granted a 20% rating for left and right lower extremity peripheral neuropathy of the sciatic nerve, and granted a TDIU from April 21, 2021.

The Board granted service connection for erectile dysfunction as secondary to hypertension and assigned a 20 percent rating for bilateral hearing loss from May 11, 2023, through August 9, 2024.